The Dr. Hyman Show cover image

Pharma Whistleblower Reveals Who Really Runs American Healthcare w/ Brigham Buhler

The Dr. Hyman Show

00:00

Navigating FDA Challenges and Healthcare Innovations

This chapter explores the FDA's hesitance to approve promising therapies like MDMA-assisted treatment and natural alternatives, spotlighting how corporate interests impact access to these innovations. The discussion extends to the potential of peptides, addressing the obstacles posed by big pharma in monopolizing these alternatives and the cost disparities with compounding pharmacies. Ultimately, it advocates for patient autonomy, reform in healthcare incentives, and the power of grassroots movements to drive systemic change.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app